기사 메일전송
Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses
  • 기사등록 2019-05-23 16:25:30
기사수정 (조회수:95건)   




Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam. 


“We look forward to presenting data at ASCO and EHA that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “These data demonstrate our continued commitment to the discovery, development and delivery of medicines for patients with cancers.” 


At ASCO, Takeda will present data from both its lung portfolio and hematology portfolio. Results from a Phase 1/2 first-in-human, open-label, multicenter study of TAK-788 will be presented orally. The ongoing study is investigating the antitumor activity and safety of TAK-788 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Takeda also will present three posters that demonstrate our commitment to furthering the understanding of patients with anaplastic lymphoma kinase-positive (ALK+) NSCLC treated with ALUNBRIG® (brigatinib). The Phase 3 PhALLCON trial - an ongoing efficacy study of ICLUSIG® (ponatinib) in combination with reduced-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) - will be featured in a poster presentation. Additional data from the ECHELON-1 and ECHELON-2 trials evaluating ADCETRIS® (brentuximab vedotin) as a frontline treatment option in patients with newly diagnosed Stage III and IV Hodgkin lymphoma and in CD30+ peripheral T-cell lymphoma, respectively, will also be shared in partnership with Seattle Genetics. 


At EHA, additional analyses from the TOURMALINE-MM3 trial, which is investigating NINLARO™ (ixazomib) as a post-transplant maintenance therapy in adult patients with multiple myeloma, will be presented, including quality of life and outcomes in patients who deepened their responses while on ixazomib maintenance. 


Furthermore, preliminary demographics, baseline characteristics and electronic patient-reported outcomes of patients enrolled in the US MM-6 trial, a study of multiple myeloma patients who transitioned from treatment with VELCADE® (bortezomib) to treatment with NINLARO, will be presented. Real-world findings will also be featured at the meeting, including results from INSIGHT-MM, a global, prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in multiple myeloma by age and geographical region. 


ADCETRIS will be featured in encore presentations including three-year results from the ECHELON-1 trial, which will be presented during an oral, as well as results from the ECHELON-2 trial. 



In Beom, KANG


noah9191@gmail.com


<저작권자 © 데일리투데이, 무단 전재 및 재배포 금지>




0
기사수정 (조회수:95건)   

다른 곳에 퍼가실 때는 아래 고유 링크 주소를 출처로 사용해주세요.

http://dailytoday.co.kr/news/view.php?idx=24919
모바일 버전 바로가기